H share | Jotup

Molecure completes successful Secondary Public Offering (SPO) of approximately PLN 50 million (USD 12 million) with proceeds to be used to fund and build a first in class, sustainable pipeline of breakthrough therapies

Retrieved on:

星期五, 七月 21, 2023

The issue price was set at PLN 18, bringing the gross value of the offering to approximately PLN 50 million.

Key Points:

The issue price was set at PLN 18, bringing the gross value of the offering to approximately PLN 50 million.
We would like to thank all investors for participating in the offering and for the trust they have placed in Molecure.
Considering the current market conditions, we view the execution of the share issue as a remarkable achievement.
Molecure estimates that the capital expenditure associated with the strategy from mid-2023 to the end of 2025 will amount to approximately PLN 250 million.

JLMAG Awards the First SGS PAS 2060 Carbon Neutrality Declaration Certificate in the Global Rare Earth Permanent Magnet Industry

Retrieved on:

星期四, 六月 30, 2022

PAS 2060 is the internationally recognized carbon neutrality standard, which requires enterprises to strive to reduce carbon emissions and achieve low-carbon production on the basis of quantifying greenhouse gas emissions.

Key Points:

PAS 2060 is the internationally recognized carbon neutrality standard, which requires enterprises to strive to reduce carbon emissions and achieve low-carbon production on the basis of quantifying greenhouse gas emissions.
With regard to carbon emissions that cannot be reduced, PAS 2060 encourages enterprises to adopt voluntarily compensation and offset to achieve carbon neutrality.
The PAS 2060 carbon neutrality declaration certificate proved that JL MAG's efforts in carbon neutrality have been highly recognized by the international authorities.
The Company facilitates the pursuit of carbon neutrality in China and around the world by providing rare earth permanent magnets to its top player customers.

JL MAG Achieved Robust Revenue and Profit Growth in 2021

Retrieved on:

星期三, 三月 30, 2022

The Company is pleased to announce its annual results for the year ended 31 December 2021 ("2021" or the "Reporting Period") today.

Key Points:

The Company is pleased to announce its annual results for the year ended 31 December 2021 ("2021" or the "Reporting Period") today.
In 2021, JL MAG continued to adhere to the core value of "Customer Orientation and Value Co-creation" and implement its corporate mission of "Employing rare earth to create better life".
The outstanding business performance of the Company replied on the significant growth in the production and sales volume of high-performance REPMs.
In 2021, the Company's revenue from NEVs and automotive parts sector amounted to RMB 1.05 billion, up by 222.7% year-on-year.

Fairfax Announces Reset Dividend Rate on its Series G Preferred Shares and Quarterly Dividend on Series C, D, E, F, G, H, I, J, K and M Preferred Shares and Quarterly Dividend Rate for Series D, F, H and J Preferred Shares

Retrieved on:

星期二, 九月 1, 2020

Financial markets, Finance, Money, Corporate finance, Stock market, Equity securities, Preferred stock, Stock, Initial public offering, Shares outstanding, H share

Holders of Series G Shares have the right, at their option, exercisable not later than 5:00 p.m. (Toronto time) on September 15, 2020, to convert all or part of their Series G Shares, on a one-for-one basis, into Cumulative Floating Rate Preferred Shares, Series H (the Series H Shares) (TSX: FFH.PR.H), effective September 30, 2020.

Key Points:

Holders of Series G Shares have the right, at their option, exercisable not later than 5:00 p.m. (Toronto time) on September 15, 2020, to convert all or part of their Series G Shares, on a one-for-one basis, into Cumulative Floating Rate Preferred Shares, Series H (the Series H Shares) (TSX: FFH.PR.H), effective September 30, 2020.
Holders of Series G Shares are not required to elect to convert all or any part of their Series G Shares into Series H Shares and holders of Series H Shares are not required to elect to convert all or any part of their Series H Shares into Series G Shares.
As provided in the share conditions of the Series G Shares and the Series H Shares: (i) if Fairfax determines that there would be fewer than 1,000,000 Series G Shares outstanding after September 30, 2020, all remaining Series G Shares will be automatically converted into Series H Shares on a one-for-one basis effective September 30, 2020 and Fairfax will cause the return of all Series H Shares tendered for conversion into Series G Shares; and (ii) if Fairfax determines that there would be fewer than 1,000,000 Series H Shares outstanding after September 30, 2020, all remaining Series H Shares will be automatically converted into Series G Shares on a one-for-one basis effective September 30, 2020 and Fairfax will cause the return of all Series G Shares tendered for conversion into Series H Shares.
The Series G Shares and the Series H Shares are listed on the Toronto Stock Exchange under the trading symbols FFH.PR.G and FFH.PR.H, respectively.

Quectel Stocks Eligible for Trading under Shanghai-HK Stock Connect

Retrieved on:

星期一, 二月 24, 2020

Shanghai Stock Exchange, Economy of Hong Kong, Shanghai-Hong Kong Stock Connect, Economies, SSE 180 Index, H share, Stock exchange, Shenzhen-Hong Kong Stock Connect

This allows international investors, both institutional and retail, to trade Quectel's stocks via the Hong Kong Stock Exchange with the stock code 93236.

Key Points:

This allows international investors, both institutional and retail, to trade Quectel's stocks via the Hong Kong Stock Exchange with the stock code 93236.
The Shanghai-Hong Kong Stock Connect program is a cross-boundary investment platform that permits investors in each market to trade shares on the opposite market using their local brokers and clearing houses.
Under this program, only those SSE-listed stocks of the SSE 180 Index and the SSE 380 Index as well as shares that are dual-listed in the two bourses (A+H shares) are eligible.
Quectel was listed on the Main Board of the SSE on July 16th, 2019, which is the largest stock exchange in China by market capitalization.

Quectel Stocks Eligible for Trading under Shanghai-HK Stock Connect

Retrieved on:

星期一, 二月 24, 2020

Shanghai Stock Exchange, Economy of Hong Kong, Shanghai-Hong Kong Stock Connect, Economies, SSE 180 Index, H share, Stock exchange, Shenzhen-Hong Kong Stock Connect

This allows international investors, both institutional and retail, to trade Quectel's stocks via the Hong Kong Stock Exchange with the stock code 93236.

Key Points:

This allows international investors, both institutional and retail, to trade Quectel's stocks via the Hong Kong Stock Exchange with the stock code 93236.
The Shanghai-Hong Kong Stock Connect program is a cross-boundary investment platform that permits investors in each market to trade shares on the opposite market using their local brokers and clearing houses.
Under this program, only those SSE-listed stocks of the SSE 180 Index and the SSE 380 Index as well as shares that are dual-listed in the two bourses (A+H shares) are eligible.
Quectel was listed on the Main Board of the SSE on July 16th, 2019, which is the largest stock exchange in China by market capitalization.

Pharmaron Lists H-Shares on the Hong Kong Stock Exchange

Retrieved on:

星期四, 十一月 28, 2019

Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Finance in China, Economy of China, Economy, A-share, H share, Hong Kong Stock Exchange

Pharmaron Beijing Co., Ltd. (Stock Code: 300759.SZ/3759.HK) announced today that 117 million H-shares are listed on the Main Board of The Stock Exchange of Hong Kong.

Key Points:

Pharmaron Beijing Co., Ltd. (Stock Code: 300759.SZ/3759.HK) announced today that 117 million H-shares are listed on the Main Board of The Stock Exchange of Hong Kong.
The successful listing of H-shares on The Stock Exchange of Hong Kong, together with the existing A-shares listing on the Shenzhen Stock Exchange (A+H dual listing), has broadened Pharmarons financing channels to support its global growth strategy.
With the strong financial support, Pharmaron will continuously strengthen its service capabilities and capacities by integrating cutting-edge science and technologies into the existing service platforms.
Our listing on The Stock Exchange of Hong Kong marks another milestone for Pharmaron, said Dr. Boliang Lou, Chairman and CEO, Pharmaron.